13F Holdings
中文EN

RNAZ Transcode Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829635 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-435.7%
TTM EPS YoY81.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-866.1%
ROA-581.7%
ROIC (approx.)-909.8%
Asset turnover—

Leverage & solvency

Liabilities / assets28.2%
Debt / equity0.00x
Current ratio0.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-476.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$13.42M$9.71M$12.26M$10.23M$2.75M
SG&A expense$5.77M$5.95M$7.15M$8.40M$3.40M
Operating income-$27.98M-$15.66M-$19.42M-$18.63M-$6.15M
Interest expense$6,616$26,813$55,899$31,986$95,070
Pretax income-$34.44M-$16.75M———
Income tax$226,069$0$0$0$53,051
Net income-$34.66M-$16.75M-$18.55M-$17.56M-$6.84M
EBITDA-$27.90M-$15.57M-$19.30M-$18.54M-$6.11M
EPS (basic)-52.59-1,336.63-3,419.01-1,082.79-0.81
EPS (diluted)-52.59-1,336.63-3,419.01-1,082.79-0.81
Weighted avg. shares (diluted)689,71312,5585,42416,2228.43M
Balance sheet
Cash & equivalents$17.81M$5.81M$2.77M$4.97M$20.83M
Current assets$21.98M$7.09M$4.46M$7.38M$22.73M
PP&E, net$370,681$51,574$120,707$208,581$206,268
Goodwill$25.74M————
Intangibles$114.30M————
Total assets$162.40M$7.29M$5.17M$7.59M$22.94M
Current liabilities$3.49M$2.77M$3.49M$4.35M$2.53M
Total liabilities$10.52M$9.31M$3.53M$4.35M$2.53M
Shareholders' equity$10.34M-$2.02M$1.64M$3.24M$20.40M
Shares outstanding916,96836,75319,01416,22212.90M
Cash flow statement
Operating cash flow-$19.52M-$13.34M-$18.07M-$15.76M-$5.27M
Capital expenditure$6,660$21,761$35,609$100,919$254,820
Free cash flow-$19.52M-$13.36M-$18.11M-$15.86M-$5.52M
Investing cash flow-$4,436-$21,761-$35,609-$100,919-$251,820
Financing cash flow$31.52M$16.40M$15.91M$5,989$25.52M
Depreciation & amortization$76,446$90,894$123,483$98,606$42,470
Stock-based compensation$485,428$1.70M$1.04M$395,329$185,996

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.